Among all subjects, participants with ER+ and PR+ (ER+/PR+) status had an increased risk of breast cancer in the highest tertile (OR = 4.29, 95% CI: 2.45–7.54 in the highest DII category, p for trend <0.0001) compared to that of individuals in the lowest tertile. Here, ESR1 is linked to breast cancer.